儿童口服固体微纳制剂研发进展

    Advances in the Development of Pediatric Oral Solid Micro-Nano Formulations

    • 摘要: 口服固体制剂具有生产效率高、药物稳定性好、储运便利等优势,是临床一线用药的主要剂型。儿童因机体代谢、吞咽功能尚未发育完善,其口服固体制剂主要适用于≥6岁患者。以多微粒系统、口崩片、微片、纳米制剂为代表的新型口服固体微纳制剂,使口服固体制剂的适用年龄大幅提前至婴幼儿阶段,能满足多数儿童口服用药需求。近年来,上述微纳制剂在制备技术、掩味工艺及临床应用方面取得诸多研究进展,也揭示了儿童口服固体微纳制剂未来的发展方向。

       

      Abstract: Oral solid dosage forms feature high manufacturing efficiency, favourable drug stability and convenient storage and transportation, and serve as the predominant dosage forms for first-line clinical therapy. Owing to immature metabolic capacity and swallowing function in paediatric populations, conventional oral solid dosage forms are mainly indicated for patients aged 6 years and above. Represented by multiparticulate systems, orally disintegrating tablets, minitablets and nanoformulations, novel oral solid micro-nano formulations have substantially extended the applicable age down to the infant stage, and can meet most oral medication demands of paediatric patients. In recent years, considerable research advances have been achieved in the preparation technologies, taste-masking processes and clinical applications of the above-mentioned micro-nano formulations, which also reveals the future development direction of paediatric oral solid micro-nano formulations.

       

    /

    返回文章
    返回